Clinical utility of a CRTH2 antagonist, OC000459, as an anti-Th2 therapy in atopic dermatitis

本研究将评价一种新型抗Th2疗法作为中重度特应性皮炎的控制性治疗，其主要目的是预防疾病发作（主要医疗负担）的发生。OC 000459是一种口服药物，可抑制Th2淋巴细胞、嗜酸性粒细胞和嗜碱性粒细胞表达的受体CRTH2。CRTH2介导这些白细胞向发炎皮肤的募集以及它们的活化以产生Th2细胞因子。CRTH2还涉及过敏性致敏过程，因此其抑制可能具有持久的疾病修饰活性，具有阻止特应性进展的潜力。OC 000459已被证明对哮喘和过敏性鼻结膜炎有效，因此具有作为单一全身治疗治疗多种共病过敏性疾病的优势。

This study will evaluate a novel anti-Th2 therapy as a controller treatment of moderate-to-severe atopic dermatitis with the primary objective to prevent occurrence of disease flares, the major healthcare burden. OC000459 is an orally administered drug that inhibits the receptor CRTH2 expressed by Th2 lymphocytes, eosinophils and basophils. CRTH2 mediates recruitment of these leukocytes to inflamed skin and their activation to elaborate Th2 cytokines. CRTH2 is also implicated in the process of allergic sensitisation and its inhibition may therefore have long lasting disease modifying activity with the potential to halt the atopic march. OC000459 has proven efficacy in asthma and allergic rhinoconjunctivitis and therefore has the advantage of treating multiple co-morbid allergic diseases as a single systemic treatment.